Loading...
Statins clearly confer an overall benefit in preventing cardiovascular (CV) morbidity and mortality, but the relative benefits in men versus women are not as clear-cut. Researchers conducted a meta-analysis of 11 randomized, placebo-controlled, secondary-prevention trials of statins for adverse cardiovascular events (43,191 patients; 21% women) with follow-up ranging from 16 weeks to 6 years. Of the 11 studies, only 3 were rated as good quality, and the 4 largest studies were rated as fair.
In pooled analyses, relative risk for any adverse CV event was about 19% lower with statins in both women and men, but relative risk for all-cause mortality or stroke was lowered significantly (by 19%) in men and nonsignificantly (by 8%) in women. Mean LD…